载脂蛋白 L1：从默默无闻到一致性再到争议。
Apolipoprotein L1: from obscurity to consistency to controversy.
机构信息
Nephrology and Hypertension Division, Georgetown University Medical Center, Washington, DC, USA.
出版信息
Kidney Int. 2015 Jan;87(1):14-7. doi: 10.1038/ki.2014.319.
Apolipoprotein L1 (APOL1) is associated with increased incidence of chronic kidney disease (CKD) and end-stage renal disease, and with faster progression of CKD, in African Americans. APOL1 is expressed in intra- and extrarenal vascular tissue, making it a candidate to explain the increased incidence of cardiovascular disease in CKD. This Commentary discusses the disparate results from three studies showing that APOL1 renal risk genotypes are either harmful, neutral, or protective in the context of cardiovascular disease.
载脂蛋白 L1（APOL1）与非裔美国人慢性肾脏病（CKD）和终末期肾病的发生率增加以及 CKD 进展加快有关。APOL1 在肾内和肾外血管组织中表达，使其成为解释 CKD 中心血管疾病发病率增加的候选因素。本评论讨论了三项研究的结果，这些研究表明，APOL1 肾脏风险基因型在心血管疾病的背景下要么有害，要么中性，要么具有保护作用。
Zotero 插件